<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163475</url>
  </required_header>
  <id_info>
    <org_study_id>BY217/M2-015</org_study_id>
    <nct_id>NCT00163475</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)</brief_title>
  <official_title>The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally&#xD;
      active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown&#xD;
      effectiveness in the treatment of asthma.&#xD;
&#xD;
      The aim of the study is to compare the effect of roflumilast on lung function, symptoms, and&#xD;
      use of rescue medication in patients with stable asthma. Roflumilast will be administered&#xD;
      orally either in the morning or in the evening at one dose level. The study duration consists&#xD;
      of a baseline period (1 to 2 weeks) and a treatment period (6 weeks). The study will provide&#xD;
      further data on safety, tolerability, and effectiveness of roflumilast.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change from randomization to endpoint in forced expiratory volume in one second.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>forced expiratory vital capacity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak expiratory flow</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morning and evening peak expiratory flow (patient's diary)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptom score and use of rescue medication (patient's diary)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of symptom-free days / rescue medication-free days asthma exacerbations.</measure>
  </secondary_outcome>
  <enrollment>511</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Diagnosis of persistent bronchial asthma (with reference to the Global Initiative for&#xD;
             Asthma Guidelines 2002)&#xD;
&#xD;
          -  Baseline FEV1 50 - 85% in patients either untreated or receiving e.g. short-acting&#xD;
             bronchodilators, DSCG, nedocromil, anticholinergics, long-acting bronchodilators,&#xD;
             theophylline/aminophylline, lipoxygenase inhibitors, leukotriene antagonists, alone or&#xD;
             in combination&#xD;
&#xD;
          -  Baseline FEV1 60 - 90% in patients receiving not more than 500 mcg BDP-CFC (or&#xD;
             equivalent) and/or in combination with any other asthma medication mentioned above&#xD;
&#xD;
          -  No change in the asthma treatment 4 weeks prior to baseline period&#xD;
&#xD;
          -  Patients who, with the exception of asthma, are in good health&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Poorly controlled asthma: requirement of a course of oral and/or parenteral&#xD;
             glucocorticosteroids 4 weeks prior to the baseline, or admission to hospital for&#xD;
             asthma (including treatment in an emergency room) 4 weeks prior to the baseline&#xD;
             period, or asthma exacerbation in the last 4 weeks prior to baseline period&#xD;
&#xD;
          -  Patient using regularly &gt;8 puffs/day rescue medication prior to baseline&#xD;
&#xD;
          -  History of lower airway infection in the last 4 weeks prior to baseline period&#xD;
&#xD;
          -  Diagnosis of chronic obstructive pulmonary disease and/or other relevant lung diseases&#xD;
&#xD;
          -  Heavy smoker: currently: &gt;20 cigarettes/day and/or &gt;10 pack years, ex-smoker: with a&#xD;
             smoking history of â‰¥10 pack years&#xD;
&#xD;
          -  Clinically relevant abnormal laboratory values suggesting an unknown disease and&#xD;
             requiring further clinical evaluation&#xD;
&#xD;
          -  Liver insufficiency (Child Pugh A or worse)&#xD;
&#xD;
          -  Active hepatitis&#xD;
&#xD;
          -  Known infection with HIV&#xD;
&#xD;
          -  Diagnosis or history of cancer (other than basal cell carcinoma) or recurrence within&#xD;
             5 years prior to study start&#xD;
&#xD;
          -  Alcohol and/or drug abuse&#xD;
&#xD;
          -  Suspected hypersensitivity and/or contraindication to any ingredients of the study&#xD;
             medication (roflumilast) or rescue medication&#xD;
&#xD;
          -  Pregnancy or patient of childbearing potential who is not using reliable method of&#xD;
             contraception&#xD;
&#xD;
          -  Patients not able to follow study procedures, e.g. due to language problems,&#xD;
             psychological disorders&#xD;
&#xD;
          -  Suspected inability or unwillingness to comply with the study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Australia</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Belgium</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in France</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in South Africa</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Spain</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>South Africa</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4473&amp;filename=BY217-M2-015-RDS-2006-06-09.pdf</url>
    <description>BY217-M2-015-RDS-2006-06-09</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Roflumilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

